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Abstract

Cardiotoxicity is a rising issue connected to use of
chemotherapy and radiotherapy in the treatment of
neoplastic diseases. Early diagnosis during follow-up
is of paramount importance, and careful surveillance is
recommended. Evaluation of left ventricular ejection fraction
by echocardiography and nuclear medicine techniques is
widely used in clinical practice; however, their sensitivity in
detecting early cardiac damage is low. New instruments like
speckle-tracking imaging, cardiac magnetic resonance and
cardiac circulating biomarkers are available to clinicians to
best evaluate the onset and progression of cardiotoxic effects,
improving the therapeutic management and final outcome for
the patient. (J Patient-Centered Res Rev. 2014;1:121-127.)
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Introduction

The introduction of chemotherapy significantly improved
the outcome of cancer patients and represents a fundamental
element in treatment of several tumors. However,
chemotherapy is associated with negative side effects
that greatly limit its use. Cardiotoxicity is one of the most
relevant issues connected to implementation of some classes
of chemotherapeutic agents because of its negative effect
on prognosis and quality of life.1 Radiotherapy directed to
the chest alone or in association with chemotherapy is an
additional cause of cardiac damage in oncologic patients.
Progressive impairment of systolic function leading to
overt heart failure is the most common manifestation
of chemotherapy-induced cardiomyopathy (CICM);
however, other complications like hypertension, acute
coronary syndrome, arrhythmias and thrombosis have been
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described. CICM is usually characterized by a long stage
of subclinical myocardial dysfunction that is not detectable
by conventional diagnostic methods but which is important
for patient prognosis. The early diagnosis and adequate
evaluation of the cardiotoxic effects of chemotherapeutic
drugs are of paramount importance for clinicians to set the
best therapeutic management.

Main Chemotherapeutic Drugs Associated
With Cardiotoxicity

Anthracyclines
Doxorubicin,
epirubicin
and
daunorubicin
are
chemotherapeutic drugs strongly associated with
cardiotoxicity, which usually occurs within 1 year of
treatment at an incidence of about 2%.2 They are widely used
in the treatment of breast cancer, lung cancer, hematological
malignancies and sarcoma. The cardiotoxic effect is related to
the cumulative dose of the drug, especially for doxorubicin,
for which 550 mg/m2 is considered the maximal accepted
threshold.3
Trastuzumab
A monoclonal antibody used in the treatment of breast
cancer that is positive for the expression of the ErbB2
growth factor receptor,4 trastuzumab generates an increase in
cardiotoxicity incidence when combined with anthracyclines.
The cardiotoxic effect is frequent, occurring in up to 28% of
patients.5
Tyrosine-Kinase Inhibitors
This category includes several drugs that share a similar
mechanism of action that consists of inhibiting different
tyrosine kinases, enzymes involved in the signal transduction
process. Imatinib, dasatinib and nilotinib inhibit ABL-kinase
and are used for treatment of some forms of leukemia;
cardiotoxic effect occurs in 1% of treated patients.6 Sunitinib
and sorafenib were designed to inhibit tyrosine kinases
involved in both tumor proliferation and angiogenesis;
3-11% of patients develop cardiotoxicity.7
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Antibody Therapies
Hypertension occurs in about 50% of bevacizumab-treated
patients; conversely, cetuximab and rituximab are associated
with severe orthostatic hypotension.8

A list describing the main features of chemotherapeutic
medications associated with cardiovascular side effects is
reported in Table 1.

Antimetabolites
Capecitabine and 5-fluorouracil are associated with
myocardial ischemia in 1.2% to 18% of treated patients.9

Radiotherapy is presently a widely used anticancer treatment.
High-dose irradiation focused on the thorax is mainly
used in the context of adjuvant treatment after surgery for
breast cancer, as adjuvant or selected therapy of lung and
esophageal cancer, and as complementary treatment for
lymphoma.11 However, radiosensitivity of the heart is one of
the most critical radiation dose-limiting factors. The outcome
of long-term cancer survivors can be affected by radiationinduced heart disease, related to the total cumulative dose of
radiotherapy (number of treatments and dose of irradiation).12
Irradiation of the heart can lead to a wide range of clinical
effects, including pericarditis, coronary artery disease
and myocardial infarction, valvular heart disease, rhythm
anomalies and nonischemic myocardial damage (restrictive
cardiomyopathy). Estimated incidence of radiation-induced
heart damage is 10-30% at 5-10 years after treatment;

Alkylating Agents
Cisplatin can induce hypertension. Myocardial ischemia,
thrombosis, acute coronary syndrome and symptomatic left
ventricular dysfunction also have been reported, mostly in
older patients. Cyclophosphamide is widely used in many
hematologic malignancies. Myocarditis can occur, with an
incidence in adults estimated at 7-25% at doses > 150 mg/kg.8
Taxanes
Docetaxel and paclitaxel induce cardiotoxicity in 2.3% to
8% of patients. They are mainly used in the treatment of
patients with breast, lung or ovarian cancer.10

Cardiovascular Complications of Radiotherapy

Table 1. Chemotherapeutic medications associated with cardiovascular side effects
Antineoplastic
Drug
mechanism
anthracyclines (cumulative dose):
doxorubicin (>500 mg/m2);
liposomial doxorubicin (>900 mg/m2); • tumor cell DNA
epirubicin (>720 mg/m2);
damage
mitoxantrone (>120 mg/m2);
idarubicin (>90 mg/m2)
• inhibition of
trastuzumab
ErbB2
imatinib, dasatinib, nilotinib

sunitinib, sorafenib

bevacizumab

5-fluorouracil

• inhibitors

of
ABL-kinase
• inhibition of
tyrosine kinases
involved in
angiogenesis
and proliferation
• v ascularendothelial
growth factor
inhibitor
•a
 lteration of
DNA structure

cisplatin

•a
 lteration of
DNA structure

cyclophosphamide

•a
 lkylation of
guanine

taxanes (paclitaxel, docetaxel)

•d
 isruption of
microtubule
function
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Malignancy

Cardiotoxic
effect

Incidence of
cardiotoxicity

Mechanism of
cardiotoxicity

• hematologic
• breast
• multiple myeloma
• lung
• sarcoma

• heart failure

• 2%

• production of free
radicals

• breast

• heart failure

• 1%–28%

• BCR/ABL-positive
• heart failure
leukemia

• 1.7%

• kidney
• gastrointestinal
stromal tumors
• hepatocarcinoma

• heart failure
• acute

coronary
• 3%–8%
syndromes
• hypertension

• colon
• lung
• glioblastoma

• hypertension

• gastrointestinal
tumors
• breast
• lung
• stomach
• bladder
• ovary
• testicle
• lymphoma
• leukemia
• lung
• ovary
• breast
• prostate

• mitochondrial
damage
• inhibition of ABL
tyrosine kinase on
cardiomyocytes
• inhibition of
tyrosine kinases
involved in
cardiomyocytes
survival

• 50%

• unknown

• myocardial
ischemia

• 1.2%–18%

• vasospasm
• autoimmune
phenomena
• myocarditis

• hypertension
• heart failure

• unknown

• oxidative stress

• myocarditis

• 7%–25%

• unknown

• heart failure

• 2.3%–8%

• lipid peroxidation
• direct cytotoxic
damage
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in these patients, cardiovascular disease is the first
nonmalignant cause of death.13 Radiation effects appear to
be accelerated by the conjunction of common cardiovascular
risk factors and to increase the risk of cardiotoxicity of some
chemotherapeutic agents, such as anthracyclines.

Manifestation of Cardiotoxicity and Main Risk
Factors

The progressive decline of left ventricular systolic and
diastolic function is the most common manifestation of
CICM. A variable long subclinical stage precedes the onset of
heart failure symptoms like dyspnea, asthenia and peripheral
edema. Cardiomyocyte damage secondary to chemotherapy
is classified in two groups. Type I chemotherapy-related
myocardial dysfunction is usually secondary to oxidative stress
(typically anthracycline-induced) and results in cardiomyocyte
death; it is an irreversible, dose-dependent process and
leads to ultrastructural alterations identifiable at myocardial
biopsy. Type II chemotherapy-related myocardial dysfunction
(typically trastuzumab-induced) is caused by cardiomyocyte
impairment rather than cell death; it is not dose-related
and may be reversible.10 Myocardial ischemia presenting
with T-wave changes, chest pain, acute coronary syndrome
and myocardial infarction is another possible cardiotoxic
effect of chemotherapeutic agents like 5-fluorouracil.14
Hypertension, hypotension and thromboembolic events are
other cardiovascular complications of cancer treatment.8,15 It
appears clear that the incidence of cardiotoxicity is related
to the presence of risk factors: young or old age, female
gender, prior mediastinal radiation therapy, hypertension, and
combined chemotherapy and presence of underlying cardiac
disease.2 The finding of any of these in a patient undergoing
chemotherapy should encourage more aggressive follow-up.

Diagnosis and Monitoring of Cardiotoxicity

Although endomyocardial biopsy remains the most sensitive
and specific method to assess cardiotoxicity by describing
the microscopic structural alterations of myocardial tissue,
its use is strongly limited because of the high invasiveness
of the procedure.16 Electrocardiographic (ECG) alterations
may occur during treatment with cancer drugs; these include
decreased QRS voltage and ST-T wave changes. However, the
most common and relevant finding consists in QT corrected
(QTc) interval prolongation.17 QTc measures the total
duration of the electric depolarization and repolarization of
myocardium; its prolongation is associated to increased risk
of ventricular arrhythmias, particularly torsades de pointes,
and sudden death. The underlying mechanism is mediated
by the interaction of chemotherapeutic drugs with the human
ether-a-go-go-related gene product, a protein subunit of a
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potassium ion channel (hERG K+).18 Although elongation of
QTc occurring during chemotherapy treatment is relatively
frequent (14% in a series of 525 patients enrolled in phase I
clinical trial)19 and ECG monitoring is strictly recommended
in the follow-up of chemotherapy-treated patients, the
association between this electric disorder and major cardiac
events has not yet been proved in this set of patients.
Imaging methods such as echocardiography are more often
used to evaluate CICM in clinical practice. Left ventricular
ejection fraction (LVEF) evaluated by two-dimensional
echocardiography is the standard parameter for assessment of
the cardiotoxic effect of chemotherapy. The Cardiac Review
and Evaluation Committee (CREC) defined that the diagnosis
of CICM can be established when at least one of the following
elements is present: 1) cardiomyopathy characterized by
a decrease in cardiac LVEF that was either global or more
severe in the septum; 2) symptoms of congestive heart failure;
3) associated signs of congestive heart failure, including but
not limited to S3 gallop, tachycardia, or both; and 4) decline
in LVEF of at least 5% to less than 55% with accompanying
signs or symptoms of congestive heart failure, or a decline in
LVEF of at least 10% to below 55% without accompanying
signs or symptoms.5 Echocardiography also can provide
important data on diastolic function that is usually altered
early on in patients who develop CICM.20 Although widely
used, LVEF measured by two-dimensional echocardiography
is calculated using some geometrical assumptions, which
influences the reproducibility of the metric. LVEF evaluation
by three-dimensional echocardiography is derived by a
volumetric analysis of the left ventricle and is free from any
geometrical assumption, resulting in a more accurate and
reproducible measurement.21 Stress echocardiography was
proposed as a method to identify early systolic dysfunction
due to chemotherapy. However, data are very poor and the
results derived from small studies have been conflicting.22
An alternative imaging method used to monitor LVEF in
chemotherapy-treated patients is represented by 99mTC
multigated radionuclide angiography (MUGA), a nuclear
imaging method able to visualize the cardiac blood pool by
γ-camera with ECG-triggered acquisitions. The final result
provides a highly reproducible and precise quantification
of left ventricular volumes and dyssynchrony that does
not derive from geometrical assumption.23 Although LVEF
evaluation using two- or three-dimensional echocardiography
or MUGA is widely used in clinical practice, it is unable to
detect the earliest myocardial impairment or predict which
patients have an increased risk for developing CICM. New
imaging techniques and biomarker evaluation are emerging
methods developed to overcome the limitation of LVEF as
the sole analysis.
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New Insights in the Early Detection of the
Myocardial Damage

Speckle-Tracking Imaging
Myocardial contraction consists of a complex spatial
deformation depending on the particular anatomical array of
the muscular fibers. The main components of deformation
are represented by longitudinal, circumferential and radial
deformation. Twist, untwist and torsion are additional
components depending on the different orientation of the
fibers between apex and base of the heart. Speckle tracking
analyzes the myocardial deformation on two- and threedimensional images by tracking natural acoustic reflections
and interference patterns, called “speckle,” within an
ultrasonic window. The analyzer software is able to provide
the percentage variation of distance (deformation) between
speckles within a predefined region of interest, obtaining a
value defined as “strain.” The velocity of the deformation
is defined as “strain rate” (Figure 1). The evaluation of
strain and strain rate in patients receiving chemotherapy
has been evaluated in several studies, which demonstrated a
concrete advantage in early identification of left ventricular
dysfunction and predicting future decline of LVEF.24,25
Cardiac Magnetic Resonance Imaging
Cardiac magnetic resonance (CMR) represents the criterion
standard method in the evaluation of cardiac volumes,
mass and function.22,25 Moreover, “tissue characterization”
performed by CMR reveals alterations like fibrosis, edema
and inflammation. In the early stage of CICM, CMR is able

to detect myocardial edema using T2-weighted sequences
and myocardial inflammation by T1-weighted fast-spin echo
sequences after administration of gadolinium.26 Delayed
sequence acquisition after contrast is used to investigate late
gadolinium enhancement, which detects tissue presenting a
slow contrast wash-out, usually consisting of scar or fibrosis.
Early alterations of late gadolinium enhancement have been
described in chemotherapy-treated patients and are predictive
of development of CICM and decline of LVEF.26 In studies
including adults who survived childhood malignancies, CMR
demonstrated individuated late effects of cardiotoxicity: the
reduction of the cardiac mass in comparison to safe controls is an
indicator of late cardiotoxicity and is associated with increased
risk of cardiac events.26 Moreover, the accurate definition
of volumes and function provided by CMR demonstrated a
higher sensibility than echocardiography in detecting minimal
alteration of LVEF with elevated reproducibility.27
Circulating Biomarkers
Injury of cardiomyocytes causes the release of substances
into the blood flow that can be used as biomarkers of
subclinical myocardial damage. Ultrasensitive troponin I
is the most reliable marker as detecting the level of the
concentration of ultrasensitive troponin I after the treatment
is predictive of development of cardiotoxicity (P=0.020;
hazard ratio 1.38 per standard deviation).28 The same
study also identified an increase of myeloperoxidase as
an indicator of cardiotoxicity, and the coexistence of the
two markers was associated with the highest risk of future
myocardial dysfunction. Contrasting opinions have been
reported about N-terminal pro–B-type natriuretic peptide
(NT-proBNP). It did not demonstrate a predictive value for
development of cardiotoxicity in the study carried out by
Ky et al.28 However, other studies showed early variation
of NT-proBNP levels can be used to identify patients at risk
of cardiotoxicity.29,30 It is clear that larger studies are needed
to confirm the potential promise of cardiac biomarkers in
the identification of subclinical cardiotoxicity induced by
chemotherapy and to provide reliable reference ranges.

Cardiotoxicity Monitoring

Figure 1. Definition of strain and strain rate. A: Strain (ε) is

defined as the difference of the initial and the final distance
between two points divided by the initial distance. Strain rate
derives from the ratio between the velocity variation and the
initial distance between two points. B: Graphical representation
of the main deformation components of the left ventricle. L0,
initial distance; L, final distance; ΔL, distance variation; Δt, time
variation; ΔV, velocity variation.
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The systematic and integrative use of these new methods
represents the future approach of clinicians to evaluate
cardiotoxicity. Although endomyocardial biopsy remains the
most sensitive and specific method to diagnose cardiac damage,
its invasiveness limits its use to the few cases in which cardiac
dysfunction is not clearly associated with chemotherapy
treatment and should not be included as a screening method.
LVEF remains the central parameter in the diagnosis and
monitoring of cardiac function in chemotherapy-treated
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patients. However, the majority of authors demonstrated that
the drop of myocardial systolic function revealed by this
parameter is a late phenomenon in the pathophysiological
mechanism of cardiotoxicity and that its evaluation alone
substantially reduces the window for prevention.31
Data derived from three-dimensional echocardiography
are more reproducible and accurate than two-dimensional
echocardiography and should be preferred, if available.
MUGA is the most used alternative to echocardiography
(particularly when a bad acoustic window is present),
and its sensitivity is comparable to three-dimensional
echocardiography;23 however, MUGA is an old technique,
born when CMR was an experimental instrument. It is less
accurate in patients with arrhythmias; moreover, its use as
a screening method significantly increases the radiation
burden for the patient. The use of three-dimensional
echocardiography and MUGA improves the accuracy and
the interobserver variability of the measurement but does
not outweigh the limitation inherent to the evaluation of
LVEF.32 Speckle-tracking echocardiography revealed good
sensitivity in detecting early myocardial impairment, and
analysis of global longitudinal strain should be performed
during follow-up, integrating the information derived
from LVEF. A decrease in global longitudinal strain
is associated with long-term reduction of LVEF (in a recent
systematic review, Thavendiranathan et al. reported that a

reduction of 10-15% in global longitudinal strain is the most
useful parameter in predicting a drop in LVEF or onset of
heart failure symptoms33); nevertheless, its most important
limitation is represented by the lack of large controlled
studies providing reliable and well-established thresholds.
CMR is the most accurate method for diagnosing alteration
of left ventricular systolic function and allows detection
of early tissue composition changes that can reflect early
manifestation of cardiotoxicity. Unfortunately, CMR’s high
cost and low availability limit its wide implementation as a
first-line screening instrument.
The usage of cardiac circulating biomarkers is an additional
emerging method for early evaluation of cardiac function
during and after chemotherapy, and the evaluation of
ultrasensitive troponin I should be considered in patients
at high risk to develop cardiotoxicity. The timing of dosage
and thresholds are not yet well-established in literature. The
guidelines of the European Society of Medical Oncology
introduced the importance of new imaging techniques and of
circulating biomarkers in the early diagnosis of cardiotoxicity,
moreover, they suggested that a greater drop in LVEF is
needed to establish diagnosis of cardiotoxicity (to 50%
instead of the 55% previously stated by the CREC).34 Table 2
summarizes the strengths and limitations of the different
methods involved in the evaluation of chemotherapyinduced cardiotoxicity.

Table 2. Strengths and limitations of the different methods used for diagnosis of cardiotoxicity
Method
Electrocardiogram
Two-dimensional echocardiogram
(ejection fraction)
Three-dimensional echocardiogram
(ejection fraction)
Multigated radionuclide angiography
(MUGA)

Strengths
•a
 vailability
• low cost
• repeatability
•a
 vailability
• repeatability
• low inter- and intraoperator variability
• independence from geometrical assumptions
•h
 igh reproducibility
• r epeatability
• low inter- and intraoperator variability
• independence from geometrical assumptions
•h
 igh reproducibility
• r epeatability

Speckle-tracking imaging

•a
 ble to detect early systolic dysfunction
• repeatability
• independence from angle

Cardiac magnetic resonance

•a
 ble to detect early systolic dysfunction
•h
 ighly reliable measure of volumes and mass
• v ery high reproducibility
• independence from geometrical assumptions
• tissue characterization
•n
 o radiation exposure

Circulating biomarkers

•h
 igh sensitiveness
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Limitations
• poor sensitivity and specificity
• unable to detect early dysfunction
• inter- and intraoperator variability
• dependency from geometrical assumptions
• unable to detect early dysfunction
• not available in all echo-labs
• unable to detect early dysfunction
• radiation exposure
• low repeatability
• not available in all echo-labs
• absence of well-established thresholds
• time-consuming
• low sensibility in patients with suboptimal
echocardiographic window
• elevated cost
• low availability
• not suitable for patients with metallic
devices
• data derived only from studies on
anthracyclines
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Figure 2 proposes a potential screening algorithm including
classic and new techniques for monitoring the cardiovascular
side effects of chemotherapy. Baseline evaluation should
include biomarker assay and echocardiography evaluation

including global longitudinal strain; in a patient with
bad acoustic window, CMR and MUGA are alternative
options. During chemotherapy, assessment of troponin I is
recommended after each cycle and evaluation of cardiac
function should be performed every 3 months. If the baseline
evaluation is normal and troponin I does not increase during
chemotherapy, the timing for the subsequent follow-up
control should be scheduled 1 year after the end of treatment.
If an increase in troponin I occurs during chemotherapy,
or the baseline evaluation is abnormal, a cardioprotection
protocol should be started and a more intensive follow-up
is needed with re-evaluation at 3 months, 6 months and
1 year and every 6 months for 2-5 years. A more aggressive
cardioprotection protocol should be considered if alteration
of biomarkers and/or LVEF or global longitudinal strain
persists.

Conclusion

Figure 2. Flow chart for diagnosis of cardiotoxicity in

chemotherapy-treated patients. Baseline evaluation includes
biomarker assay and computing of left ventricular ejection fraction
(LVEF) and global longitudinal strain (GLS). LVEF derived by
three-dimensional (3D) echocardiography is more accurate and
reproducible and therefore preferred; if the acoustic window is poor,
cardiac magnetic resonance (CMR) or multigated radionuclide
angiography (MUGA) are alternative methods. Patients
presenting with normal LVEF and troponin I (TnI) at baseline
should be evaluated every 3 months during chemotherapy. If TnI
increase does not occur during chemotherapy, the subsequent
follow-up should be scheduled 1 year after the end of treatment.
If baseline LVEF or TnI are abnormal, a cardioprotection protocol
is needed and a more intensive follow-up should be established
with evaluation at 3 months, 6 months and 1 year after the end
of treatment and every 6 months for 2-5 years. At every control,
a drop of 10% of LVEF (below 50%) or GLS is considered a
manifestation of cardiotoxicity and should be treated with a
cardioprotective protocol. BNP, B-type natriuretic peptide; usTnI,
ultrasensitive troponin I.
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In the last decades, the development of a wide number
of chemotherapeutic agents has permitted a substantial
improvement of survival among cancer patients.
Cardiotoxicity represents a rising problem affecting
chemotherapy-treated patients. Although anthracyclines
and herceptin are the drugs more frequently associated with
cardiotoxicity, many other pharmaceutical classes have
demonstrated cardiovascular side effects. Despite using
left ventricular ejection fraction to evaluate cardiotoxic
effect as recommended by the guidelines, it is widely
accepted that this method is not sensitive in detecting
early myocardial impairment, reducing the window for
prevention and negatively influencing prognosis. The use of
new techniques like deformation analysis, cardiac magnetic
resonance and dosage of cardiac biomarkers demonstrated
more sensitivity in detecting early cardiotoxicity,
improving prognosis and quality of life of cancer patients.
However, the fragmentary data derive from relatively small
studies, thus larger controlled trials are needed to clearly
define thresholds and screening protocols. Finally, we want
to emphasize the importance of the close collaboration
between cardiologists and oncologists for the correct
management of chemotherapy-treated patients.
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